BIOMAT Database Logo BIOMAT Database Logo

Survival benefit of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after anatomical hepatectomy. 2023

Tai-Wei Ye, and Dong-Dong Wang, and Wen-Feng Lu, and Ya-Ming Xie, and Fei-Qi Xu, and Tian-Wei Fu, and Kang-Jun Zhang, and Si-Yu Liu, and Gui-Lin Xie, and Jian Cheng, and Kai Jiang, and Zun-Qiang Xiao, and Wei-Feng Yao, and Guo-Liang Shen, and Jun-Wei Liu, and Dong-Sheng Huang, and Cheng-Wu Zhang, and Lei Liang
General Surgery, Cancer Center, Department of Hepatobiliary and Pancreatic Surgery and Minimal Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.

Although anatomical hepatectomy (AH) is widely used in the treatment of hepatocellular carcinoma (HCC), the prognosis is still unsatisfactory. The present study aimed to evaluate the survival benefit of adjuvant transcatheter arterial chemoembolization (TACE) for patients with HCC after AH. A total of 832 patients were stratified into with adjuvant TACE (443, 53.2%) and without adjuvant TACE group (389, 46.8%) AH. Propensity score matching (PSM) was performed to control for confounding factors, and multivariable Cox regression was performed to determine the independent risk factors. After PSM, the results showed that the adjuvant TACE group had better overall survival (OS) and recurrence-free survival (RFS). Among the patients with tumor recurrence, adjuvant TACE was associated with a high rate of early-stage tumor at recurrence, a lower recurrence rate around the frontal margin and extrahepatic metastases, and a higher rate of receiving curative treatment. Multivariable Cox regression analysis showed that adjuvant TACE was an independent prognostic factor for OS (HR 0.673, P = 0.001) and RFS (HR 0.650, P = 0.001). Patients with HCC after AH can benefit from postoperative adjuvant TACE. Therefore, adjuvant TACE should be considered for patients with a high risk of recurrence.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D006498 Hepatectomy Excision of all or part of the liver. (Dorland, 28th ed) Hepatectomies
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D016461 Chemoembolization, Therapeutic Administration of antineoplastic agents together with an embolizing vehicle. This allows slow release of the agent as well as obstruction of the blood supply to the neoplasm. Therapeutic Chemoembolization,Chemoembolizations, Therapeutic,Therapeutic Chemoembolizations

Related Publications

Tai-Wei Ye, and Dong-Dong Wang, and Wen-Feng Lu, and Ya-Ming Xie, and Fei-Qi Xu, and Tian-Wei Fu, and Kang-Jun Zhang, and Si-Yu Liu, and Gui-Lin Xie, and Jian Cheng, and Kai Jiang, and Zun-Qiang Xiao, and Wei-Feng Yao, and Guo-Liang Shen, and Jun-Wei Liu, and Dong-Sheng Huang, and Cheng-Wu Zhang, and Lei Liang
Hepatectomy plus adjuvant transcatheter arterial chemoembolization improves the survival rate of patients with multicentric occurrence of hepatocellular carcinoma.
November 2018, Oncology letters,
Tai-Wei Ye, and Dong-Dong Wang, and Wen-Feng Lu, and Ya-Ming Xie, and Fei-Qi Xu, and Tian-Wei Fu, and Kang-Jun Zhang, and Si-Yu Liu, and Gui-Lin Xie, and Jian Cheng, and Kai Jiang, and Zun-Qiang Xiao, and Wei-Feng Yao, and Guo-Liang Shen, and Jun-Wei Liu, and Dong-Sheng Huang, and Cheng-Wu Zhang, and Lei Liang
Transcatheter arterial chemoembolization confers survival benefit in patients with a spontaneously ruptured hepatocellular carcinoma.
June 2012, European journal of gastroenterology & hepatology,
Tai-Wei Ye, and Dong-Dong Wang, and Wen-Feng Lu, and Ya-Ming Xie, and Fei-Qi Xu, and Tian-Wei Fu, and Kang-Jun Zhang, and Si-Yu Liu, and Gui-Lin Xie, and Jian Cheng, and Kai Jiang, and Zun-Qiang Xiao, and Wei-Feng Yao, and Guo-Liang Shen, and Jun-Wei Liu, and Dong-Sheng Huang, and Cheng-Wu Zhang, and Lei Liang
Postoperative Adjuvant Transcatheter Arterial Chemoembolization After R0 Hepatectomy Improves Outcomes of Patients Who have Hepatocellular Carcinoma with Microvascular Invasion.
April 2016, Annals of surgical oncology,
Tai-Wei Ye, and Dong-Dong Wang, and Wen-Feng Lu, and Ya-Ming Xie, and Fei-Qi Xu, and Tian-Wei Fu, and Kang-Jun Zhang, and Si-Yu Liu, and Gui-Lin Xie, and Jian Cheng, and Kai Jiang, and Zun-Qiang Xiao, and Wei-Feng Yao, and Guo-Liang Shen, and Jun-Wei Liu, and Dong-Sheng Huang, and Cheng-Wu Zhang, and Lei Liang
Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization.
July 2019, European journal of gastroenterology & hepatology,
Tai-Wei Ye, and Dong-Dong Wang, and Wen-Feng Lu, and Ya-Ming Xie, and Fei-Qi Xu, and Tian-Wei Fu, and Kang-Jun Zhang, and Si-Yu Liu, and Gui-Lin Xie, and Jian Cheng, and Kai Jiang, and Zun-Qiang Xiao, and Wei-Feng Yao, and Guo-Liang Shen, and Jun-Wei Liu, and Dong-Sheng Huang, and Cheng-Wu Zhang, and Lei Liang
Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus.
September 2009, American journal of surgery,
Tai-Wei Ye, and Dong-Dong Wang, and Wen-Feng Lu, and Ya-Ming Xie, and Fei-Qi Xu, and Tian-Wei Fu, and Kang-Jun Zhang, and Si-Yu Liu, and Gui-Lin Xie, and Jian Cheng, and Kai Jiang, and Zun-Qiang Xiao, and Wei-Feng Yao, and Guo-Liang Shen, and Jun-Wei Liu, and Dong-Sheng Huang, and Cheng-Wu Zhang, and Lei Liang
Recurrent hepatocellular carcinoma after partial hepatectomy: value of treatment with transcatheter arterial chemoembolization.
June 1991, AJR. American journal of roentgenology,
Tai-Wei Ye, and Dong-Dong Wang, and Wen-Feng Lu, and Ya-Ming Xie, and Fei-Qi Xu, and Tian-Wei Fu, and Kang-Jun Zhang, and Si-Yu Liu, and Gui-Lin Xie, and Jian Cheng, and Kai Jiang, and Zun-Qiang Xiao, and Wei-Feng Yao, and Guo-Liang Shen, and Jun-Wei Liu, and Dong-Sheng Huang, and Cheng-Wu Zhang, and Lei Liang
[The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma].
May 1999, Zhonghua zhong liu za zhi [Chinese journal of oncology],
Tai-Wei Ye, and Dong-Dong Wang, and Wen-Feng Lu, and Ya-Ming Xie, and Fei-Qi Xu, and Tian-Wei Fu, and Kang-Jun Zhang, and Si-Yu Liu, and Gui-Lin Xie, and Jian Cheng, and Kai Jiang, and Zun-Qiang Xiao, and Wei-Feng Yao, and Guo-Liang Shen, and Jun-Wei Liu, and Dong-Sheng Huang, and Cheng-Wu Zhang, and Lei Liang
Successful left hepatectomy for hepatocellular carcinoma in a child after transcatheter arterial chemoembolization: report of a survival.
February 1993, European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie,
Tai-Wei Ye, and Dong-Dong Wang, and Wen-Feng Lu, and Ya-Ming Xie, and Fei-Qi Xu, and Tian-Wei Fu, and Kang-Jun Zhang, and Si-Yu Liu, and Gui-Lin Xie, and Jian Cheng, and Kai Jiang, and Zun-Qiang Xiao, and Wei-Feng Yao, and Guo-Liang Shen, and Jun-Wei Liu, and Dong-Sheng Huang, and Cheng-Wu Zhang, and Lei Liang
[The effect of postoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma].
May 2002, Zhonghua wai ke za zhi [Chinese journal of surgery],
Tai-Wei Ye, and Dong-Dong Wang, and Wen-Feng Lu, and Ya-Ming Xie, and Fei-Qi Xu, and Tian-Wei Fu, and Kang-Jun Zhang, and Si-Yu Liu, and Gui-Lin Xie, and Jian Cheng, and Kai Jiang, and Zun-Qiang Xiao, and Wei-Feng Yao, and Guo-Liang Shen, and Jun-Wei Liu, and Dong-Sheng Huang, and Cheng-Wu Zhang, and Lei Liang
The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma.
December 2000, Cancer,
Copied contents to your clipboard!